vericiguat
Selected indexed studies
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. (N Engl J Med, 2020) [PMID:32222134]
- Vericiguat. (, 2012) [PMID:37384750]
- Vericiguat. (Hosp Pharm, 2023) [PMID:37711406]
_Worker-drafted node — pending editorial review._
Connections
vericiguat is a side effect of
Sources
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. (2020) pubmed
- Vericiguat. (2012) pubmed
- Vericiguat. (2023) pubmed
- Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science. (2023) pubmed
- Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial. (2025) pubmed
- Vericiguat attenuates doxorubicin-induced cardiotoxicity through the PRKG1/PINK1/STING axis. (2024) pubmed
- Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. (2025) pubmed
- Vericiguat: First Approval. (2021) pubmed
- Vericiguat for chronic heart failure. (2023) pubmed
- The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice. (2025) pubmed